NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 14:22
Last Report Issued 03/20/2017 09:04

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 9176SP-POS
Patient ID 9176SP-POS
Chain 17000465
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 17000465

Received 03/10/2017 09:55

Sample ID 17000465-001
Matrix Serum or Plasma
Patient Name 9176SP-POS
Patient ID 9176SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
9176SP Fentanyl and Metabolite Screen, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Fentanyl	See Comment	ng/mL	0.10	
Synonym(s): Sublimaze®; Duragesic®				
Immediately following a single 2 mcg/kg I.V. dose: Up to 11 ng/mL, declining to 1 ng/mL after one hour. Following the application of a 100 mcg/hour transdermal patch, serum levels (after an initial lag time of approximately six hours) of 0.8 - 2.6 ng/mL were maintained for more than 24 hours after application. Peak plasma levels following a single oral transmucosal dose (Fentanyl Oralet) of 15 mcg/kg to children: 2 - 4 ng/mL at 20 minutes. Substance(s) known to interfere with the identity and/or quantity of the reported result: 4-methylphenethyl acetyl fentanyl				
Norfentanyl	See Comment	ng/mL	0.20	
Synonym(s): Fentanyl Metabolite				
Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).				

Results for sample 17000465-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 17000465-001
Matrix Serum or Plasma
Patient Name 9176SP-POS
Patient ID 9176SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Substance(s) known to interfere with the identity and/or quantity of the reported result: Benzyl Fentanyl				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

5640SP Fentanyl and Metabolite Confirmation, Serum/Plasma

Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)

Fentanyl	50	ng/mL	0.10	ELEVATED
Synonym(s): Duragesic®; Sublimaze®				
Immediately following a single 2 mcg/kg I.V. dose: Up to 11 ng/mL, declining to 1 ng/mL after one hour. Following the application of a 100 mcg/hour transdermal patch, serum levels (after an initial lag time of approximately six hours) of 0.8 - 2.6 ng/mL were maintained for more than 24 hours after application. Peak plasma levels following a single oral transmucosal dose (Fentanyl Oralet) of 15 mcg/kg to children: 2 - 4 ng/mL at 20 minutes. Substance(s) known to interfere with the identity and/or quantity of the reported result: 4-methylphenethyl acetyl fentanyl				
Norfentanyl	50	ng/mL	0.20	
Synonym(s): Fentanyl Metabolite				
Substance(s) known to interfere with the identity and/or quantity of the reported result: Benzyl Fentanyl				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.